Literature DB >> 25592324

Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: in vitro, rat in situ and human in vivo studies.

Jef Stappaerts1, Sophie Geboers1, Jan Snoeys2, Joachim Brouwers1, Jan Tack3, Pieter Annaert1, Patrick Augustijns4.   

Abstract

The aim of this study was to evaluate the intestinal disposition of abiraterone acetate, an ester prodrug of the anticancer agent abiraterone. Stability of the prodrug and solubility and dissolution characteristics of both abiraterone and abiraterone acetate were monitored in vitro. Moreover, the in vivo intraluminal concentrations of abiraterone and abiraterone acetate upon intake of one tablet of 250 mg abiraterone acetate were assessed in healthy volunteers. The intestinal absorption resulting from the intraluminal behavior of the ester prodrug was determined using the rat in situ intestinal perfusion technique with mesenteric blood sampling. Simulated and aspirated human intestinal fluids of the fasted state were used as solvent systems. Upon incubation of abiraterone acetate in human intestinal fluids in vitro, rapid hydrolysis of the prodrug was observed, generating abiraterone concentrations largely exceeding the apparent solubility of abiraterone, suggesting the existence of intestinal supersaturation. These findings were confirmed in vivo, by intraluminal sampling of duodenal fluids upon oral intake of an abiraterone acetate tablet by healthy volunteers. Rat in situ intestinal perfusion experiments performed with suspensions of abiraterone and abiraterone acetate in human intestinal fluids of the fasted state revealed significantly higher flux values upon perfusion with the prodrug than with abiraterone. Moreover, rat in situ intestinal perfusion with abiraterone acetate suspensions in simulated fluids of the fasted state in presence or absence of esterases demonstrated that increased hydrolytic activity of the perfusion medium was beneficial to the intestinal absorption of abiraterone. In conclusion, the rapid hydrolysis of abiraterone acetate in the intraluminal environment appears to result in fast and extensive generation of abiraterone supersaturation, creating a strong driving force for abiraterone absorption.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Abiraterone; Ester prodrug; Human intestinal fluids; Intestinal perfusion; Intraluminal degradation; Intraluminal supersaturation

Mesh:

Substances:

Year:  2015        PMID: 25592324     DOI: 10.1016/j.ejpb.2015.01.001

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  7 in total

Review 1.  Quantitative mass spectrometry methods for pharmaceutical analysis.

Authors:  Glenn Loos; Ann Van Schepdael; Deirdre Cabooter
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2016-10-28       Impact factor: 4.226

Review 2.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

3.  Development of Abiraterone Acetate Nanocrystal Tablets to Enhance Oral Bioavailability: Formulation Optimization, Characterization, In Vitro Dissolution and Pharmacokinetic Evaluation.

Authors:  Yuanfen Liu; Yuqi Li; Pengcheng Xu; Yan Shen; Baoqiang Tang; Qiyue Wang
Journal:  Pharmaceutics       Date:  2022-05-26       Impact factor: 6.525

4.  Investigating the Mechanisms behind the Positive Food Effect of Abiraterone Acetate: In Vitro and Rat In Situ Studies.

Authors:  Marlies Braeckmans; Patrick Augustijns; Raf Mols; Cécile Servais; Joachim Brouwers
Journal:  Pharmaceutics       Date:  2022-04-28       Impact factor: 6.525

5.  Supersaturated-Silica Lipid Hybrids Improve in Vitro Solubilization of Abiraterone Acetate.

Authors:  Hayley B Schultz; Paul Joyce; Nicky Thomas; Clive A Prestidge
Journal:  Pharm Res       Date:  2020-03-31       Impact factor: 4.200

6.  Improved Dissolution and Pharmacokinetics of Abiraterone through KinetiSol® Enabled Amorphous Solid Dispersions.

Authors:  Urvi Gala; Dave Miller; Robert O Williams
Journal:  Pharmaceutics       Date:  2020-04-14       Impact factor: 6.321

7.  Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system.

Authors:  Jong Bong Lee; Atheer Zgair; Jed Malec; Tae Hwan Kim; Min Gi Kim; Joseph Ali; Chaolong Qin; Wanshan Feng; Manting Chiang; Xizhe Gao; Gregory Voronin; Aimie E Garces; Chun Long Lau; Ting-Hoi Chan; Amy Hume; Tecashanell M McIntosh; Fadi Soukarieh; Mohammed Al-Hayali; Elena Cipolla; Hilary M Collins; David M Heery; Beom Soo Shin; Sun Dong Yoo; Leonid Kagan; Michael J Stocks; Tracey D Bradshaw; Peter M Fischer; Pavel Gershkovich
Journal:  J Control Release       Date:  2018-07-18       Impact factor: 9.776

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.